A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age
← catalyst calendarNCT07730450 · readout in 366 d
Sponsored by BioNTech SE (industry) · BNTX — their whole pipeline →. With Pfizer.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Prevention
Enrollment
200estimated
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-23 | actual | When the study began enrolling |
| Primary completion | 2027-08-20 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-08-20 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- COVID-19 Vaccines
Interventions
- Biological: BNT162b2 Vaccine
- Biological: Tdap Vaccine
Primary outcomes
what the primary-completion date above is the date OFPercentage of participants reporting local reactions or systemic events
measured From Day 1 up to 7 days after Vaccination
Percentage of participants reporting adverse events
measured From Day 1 through 1 month after vaccination
Percentage of participants reporting serious adverse events
measured From Day 1 through 12 months after vaccination
Spike protein levels
measured Up to 12 months after vaccination
Permalink · BNTX's whole pipeline · Catalyst calendar · Every registered study · What changed